Back to results
US 2021/0260083 A1Published application
Methods of treating heart failure with reduced ejection fraction
AssigneeAstraZeneca AB
InventorAnna Maria LANGKILDE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAstraZeneca AB
InventorAnna Maria LANGKILDE
Estimating the term…
The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.
1-107. (canceled)
A method of reducing the risk of cardiovascular death and worsening heart failure in a patient with heart failure with reduced ejection fraction (HFrEF), comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin,
A method of reducing the risk of hospitalization for heart failure and cardiovascular death in a patient following an acute myocardial infarction, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin,
A method of reducing the risk of cardiovascular death or worsening heart failure symptoms in patients with acute decompensated heart failure, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin;
Dependencies are inferred from the claim text.